观察¹²⁵I粒子植入联合引流治疗巨大肿瘤伴液化坏死的临床疗效。

选取2014年12月至2015年7月河北省肿瘤放射性粒子植入诊疗中心收治的3例巨大肿瘤伴有液化坏死患者，1例为甲状腺乳头状癌，1例为腹膜后恶性平滑肌瘤，1例为食管癌胸壁转移瘤。3例患者均行¹²⁵I粒子植入治疗，植入¹²⁵I粒子90~113颗，粒子活度0.4~0.6 mCi，周边剂量40~80 Gy。3例患者均行液化坏死物引流，其中1例为切开引流，2例为穿刺置管引流。

3例患者引流出液体量200~2 400 ml，粒子植入术后达完全缓解2例，部分缓解1例，均未出现发热、感染等并发症。

¹²⁵I粒子植入联合引流治疗巨大肿瘤伴液化坏死患者安全有效，该研究为临床治疗此类肿瘤提供新的临床治疗思路。

To discuss the therapeutic effectiveness of ¹²⁵I seeds combined with drainage in the treatment of large tumors with liquefaction necrosis.

There were three patients in the study, including 1 case of thyroid papillary carcinoma, 1 case of abdominal malignant leiomyoma, and 1 case of esophageal cancer metastases to the chest wall. Three patients underwent ¹²⁵I seeds implantation under ultrasound and CT guidance. The activity of ¹²⁵I seeds ranged from 0.4 to 0.6 mCi and the D90 of the tumor ranged from 40 to 80 Gy. Liquefaction necrosis drainage was used in all 3 cases, including 1 case of incision drainage and 2 cases of drainage tube. The efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) in 2000.

The volume of drainage was 200-2400 ml. The results showed complete remission in 2 cases after 5 months and 1 month of surgery respectively and partial remission in 1 case after 4 months of surgery, while no ¹²⁵I seeds-related adverse reactions such as fever and infection were observed.

¹²⁵I seeds implantation combined with drainage in the treatment of large tumors with liquefaction necrosis is safe and effective, and this study provides a new idea for clinical treatment of this kind of tumors.